Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2023

15.08.2023 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Race as a Component of Cardiovascular Disease Risk Prediction Algorithms

verfasst von: Ramachandran S. Vasan, Shreya Rao, Edwin van den Heuvel

Erschienen in: Current Cardiology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Several prediction algorithms include race as a component to account for race-associated variations in disease frequencies. This practice has been questioned recently because of the risk of perpetuating race as a biological construct and diverting attention away from the social determinants of health (SDoH) for which race might be a proxy. We evaluated the appropriateness of including race in cardiovascular disease (CVD) prediction algorithms, notably the pooled cohort equations (PCE).

Recent Findings

In a recent investigation, we reported substantial and biologically implausible differences in absolute CVD risk estimates upon using PCE for predicting CVD risk in Black and White persons with identical risk factor profiles, which might result in differential treatment decisions based solely on their race.

Summary

We recommend the development of raceless CVD risk prediction algorithms that obviate race-associated risk misestimation and racializing treatment practices, and instead incorporate measures of SDoH that mediate race-associated risk differences.
Literatur
1.
2.
Bonnett LJ, Snell KIE, Collins GS, Riley RD. Guide to presenting clinical prediction models for use in clinical settings. BMJ. 2019;365: l737.PubMedCrossRef
3.
Bowerman C, Bhakta NR, Brazzale D, Cooper BR, Cooper J, Gochicoa-Rangel L, et al. A race-neutral approach to the interpretation of lung function measurements. Am J Respir Crit Care Med. 2023;207(6):768–74.PubMedCrossRef
4.
•• Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268–88. e1. This report from the National Kidney Foundation and American Society of Nephrology summarizes their recommendation to replace existing race-based GFR calculations with the non-race-based CKD-Epi eGFR-cystatin-C formula. The authors, writing on behalf of the joint task force, discuss their approach to evaluating various alternative formulas based on considerations of performance as well as how each reflected population diversity and impacted clinical care, surveillance efforts, and research.
5.
Khan SS, Ning H, Shah SJ, Yancy CW, Carnethon M, Berry JD, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388–97.PubMedPubMedCentralCrossRef
6.
Medrano D, Matsumoto M, Flores E, Dako F. Understanding race-based medicine and its impact on radiology. J Am Coll Radiol. 2023.
7.
Siddique SM, May FP. Race-based clinical recommendations in gastroenterology. Gastroenterology. 2022;162(2):408–14. e2.
8.
•• Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight—reconsidering the use of race correction in clinical algorithms. New England Journal of Medicine: Mass Medical Soc. 2020;874–82. This perspective presents a description of the application of race corrections in various clinical risk estimations across specialties, and outlines ways in which incorporation of race in each of these scenarios may contribute to differential provision of resources and care by race. The authors caution against indiscriminate incorporation of race into clinical risk formulas and argue that where race is associated with clinical outcomes, investigators should consider what this relationship may represent and how adjustment for race may impact allocation of care and resources.
9.
• Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, Barr RG, et al. Reconsidering the utility of race-specific lung function prediction equations. Am J Respir Crit Care Med 2022;205(7):819–829. This study examines the use of race-specific equations for estimating lung function in the care and management of patients with COPD. Authors report on results using both race-specific and universally applied formulas and find that use of a race-specific formula resulted in underestimates of disease severity in Black individuals as assessed by symptoms, 6-min walk distance, and radiographic findings. They additionally report that adjustment for SDOH information attenuated the previously reported relationships between race and lung function, suggesting that these differences may be at least partly attributed to social factors.
10.
Elmaleh-Sachs A, Balte P, Oelsner EC, Allen NB, Baugh A, Bertoni AG, et al. Race/ethnicity, spirometry reference equations, and prediction of incident clinical events: the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Am J Respir Crit Care Med. 2022;205(6):700–10.PubMedCrossRef
11.
Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to estimate kidney function. JAMA. 2019;322(2):113–4.
12.
Kelso JM. How to deconstruct “race” and spirometry. J Allergy Clin Immunol Pract. 2022;10(9):2488–9.
13.
•• Mohottige D, Boulware LE, Ford CL, Jones C, Norris KC. Use of race in kidney research and medicine: concepts, principles, and practice. Clin J Am Soc Nephrol. 2022;17(2):314–22. In this review, authors define the terms race essentialism, racism, race, and genetic ancestry as they impact disparities in health outcomes and the provision of health services. The authors emphasize that genetic bases of race have no scientific validity and implications that racial groups are defined by unique biological traits reflect antiquated notions of race essentialism. They advocate for a race-conscious approach that acknowledges the social importance of race as a reflection of the effects of racism and promotes a health equity–minded approach to studying and using race in clinical care.
14.
Norris KC, Eneanya ND, Boulware LE. Removal of race from estimates of kidney function: first, do no harm. JAMA. 2021;325(2):135–7.PubMed
15.
• Powe NR. Black kidney function matters: use or misuse of race? JAMA. 2020;324(8):737–8. This editorial summarizes the challenges surrounding both inclusion and simple elimination of race in the estimation of GFR. The author acknowledges the role for “raceless” markers, such as muscle mass in the context of GFR estimation, in providing more precise estimations of population heterogeneity in kidney filtration than race alone.
16.
Vyas DA, James A, Kormos W, Essien UR. Revising the atherosclerotic cardiovascular disease calculator without race. The Lancet Digital health. 2022;4(1):e4–5.PubMedCrossRef
17.
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;129(25_suppl_2):S49-S73.
18.
Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982;103(6):1031–9.PubMedCrossRef
19.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.
20.
Anderson KM, Wilson P, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83(1):356–62.PubMedCrossRef
21.
Committee NCEPC. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 1994;89(3):1333–445.
22.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef
23.
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.PubMedCrossRef
24.
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9.PubMedCrossRef
25.
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51.PubMedPubMedCentralCrossRef
26.
Velarde G, Bravo-Jaimes K, Brandt EJ, Wang D, Douglass P, Castellanos LR, et al. Locking the revolving door: racial disparities in cardiovascular disease. J Am Heart Assoc. 2023;12(8):e025271.PubMedPubMedCentralCrossRef
27.
Carnethon MR, Pu J, Howard G, Albert MA, Anderson CA, Bertoni AG, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136(21):e393–423.PubMedCrossRef
28.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646.PubMedPubMedCentral
29.
• Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min Y-I, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169(1):20–29. This study was critical in highlighting the shortcomings of the traditional PCE in risk estimation, particularly among under-represented minority groups. The authors present a revised PCE using more contemporary cohort data and statistical methods intended to avoid overfitting, resulting in a reduction, but not elimination, in risk overestimation across populations and in extreme and implausible values in subpopulations.
30.
•• Vasan RS, van den Heuvel E. Differences in estimates for 10-year risk of cardiovascular disease in Black versus White individuals with identical risk factor profiles using pooled cohort equations: an in silico cohort study. Lancet Digit Health. 2022;4(1):e55–e63. In this in silico analysis of the Pooled Cohort Equations, authors demonstrate substantial and implausible differences in cardiovascular disease risk estimation between White and Black individuals using similar hypothetical risk factor profiles. Overall, they find that the PCE more commonly overestimated risk among Black men and women, frequently resulting in divergent clinical recommendations by categorizing patients on either side of the statin treatment threshold.
31.
Fleisher W, editor. What’s fair about individual fairness? Proceedings of the 2021 AAAI/ACM Conference on AI, Ethics, and Society; 2021.
32.
Braun L, Grisson R. Race, Lung function, and the historical context of prediction equations. JAMA Network Open. 2023;6(6):e2316128-e.
33.
•• Wright JL, Davis WS, Joseph MM, Ellison AM, Heard-Garris NJ, Johnson TL et al. Eliminating race-based medicine. Pediatrics. 2022;150(1):e2022057998. In this review, authors describe examples of race-based practices across medical specialties on behalf of the American Association of Pediatrics. In discussing the role of race in risk estimation using the PCE, authors call for revision of the race-based PCE to address previously identified misestimation of cardiovascular disease risk on the basis of race alone.
34.
35.
• Kaufman JS, Cooper RS. Commentary: considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol. 2021;154(4):291–298. In this commentary, authors review methodological considerations for the use of race and ethnicity in biological research. They emphasize the importance of distinguishing between studies of race, which imply biological causation in race-related differences, and those of racism, that draw attention to causal social factors and relationships that drive race-related differences.
36.
Krieger N. Refiguring, “race”: epidemiology, racialized biology, and biological expressions of race relations. Int J Health Serv. 2000;30(1):211–6.PubMedCrossRef
37.
38.
Lin SS, Kelsey JL. Use of race and ethnicity in epidemiologic research: concepts, methodological issues, and suggestions for research. Epidemiol Rev. 2000;22(2):187–202.PubMedCrossRef
39.
• Popejoy AB, Crooks KR, Fullerton SM, Hindorff LA, Hooker GW, Koenig BA, et al. Clinical genetics lacks standard definitions and protocols for the collection and use of diversity measures. Am J Hum Genet. 2020;107(1):72–82. This survey of clinical genetics professionals demonstrates heterogeneity in beliefs around the information captured in measures of race, ethnicity, and genetic ancestry, and in the appropriate use of such data in clinical genetics practice. The authors highlight the need for standardization and evidence-based approaches to interpreting and utilizing this data given the potential implications for precision-based medical care.
40.
Malinowska JK, Żuradzki T. Towards the multileveled and processual conceptualisation of racialised individuals in biomedical research. Synthese. 2022;201(1):11.PubMedPubMedCentralCrossRef
41.
Solar O, Irwin A. A conceptual framework for action on the social determinants of health. Geneva, Switzerland: WHO; 2010. [September 22, 2016]. (Social determinants of health discussion paper 2 (policy and practice)).
42.
•• Bundy JD, Mills KT, He H, LaVeist TA, Ferdinand KC, Chen J, et al. Social determinants of health and premature death among adults in the USA from 1999 to 2018: a national cohort study. Lancet Public Health. 2023;8(6):e422–e431. This study examined the mediating role of SDOH in contributing to racial disparities in premature all-cause mortality in a community-based cohort sampled from the National Health and Nutrition Examination Survey. The authors demonstrate that adjustment for eight self-reported SDOH variables accounted for all of the difference in mortality observed by race, and that adverse SDOH traits had a multiplicative effect on risk, such that each additionally SDOH risk factor reported by a participant resulted in a significantly higher risk of premature death. The findings are novel in demonstrating how incorporation of causative socioeconomic factors in observational data may explain differences observed by race and how adverse SDOH factors may interact in driving higher risk of disease.
43.
Hacker K, Auerbach J, Ikeda R, Philip C, Houry D. Social determinants of health-an approach taken at CDC. Journal of public health management and practice : JPHMP. 2022;28(6):589–94.PubMedCrossRef
44.
Braveman P, Gottlieb L. The social determinants of health: it’s time to consider the causes of the causes. Public Health Rep. 2014;129(1_suppl2):19–31.
45.
Brandt EJ. Social determinants of racial health inequities. The Lancet Public Health. 2023;8(6):e396–7.PubMedCrossRef
46.
Braveman P, Parker Dominguez T. Abandon “race.” Focus on racism. Front Public Health. 2021;9:689462.
47.
Duster T. Race and reification in science. Am Assoc Adv Sci. 2005;1050–1.
48.
Cerdeña JP, Plaisime MV, Tsai J. From race-based to race-conscious medicine: how anti-racist uprisings call us to act. The Lancet. 2020;396(10257):1125–8.CrossRef
49.
Peressini AF. Against the philosophical project of “biologizing” race. Metaphilosophy. 2021;52(5):593–615.CrossRef
50.
Robinson WS. Ecological correlations and the behavior of individuals. Int J Epidemiol. 2009;38(2):337–41.PubMedCrossRef
51.
52.
Prosperi M, Guo Y, Sperrin M, Koopman JS, Min JS, He X, et al. Causal inference and counterfactual prediction in machine learning for actionable healthcare. Nature Machine Intelligence. 2020;2(7):369–75.CrossRef
53.
54.
Piccininni M, Konigorski S, Rohmann JL, Kurth T. Directed acyclic graphs and causal thinking in clinical risk prediction modeling. BMC Med Res Methodol. 2020;20(1):179.
55.
Peters J, Bühlmann P, Meinshausen N. Causal inference by using invariant prediction: identification and confidence intervals. J R Stat Soc Ser B (Statistical Methodology). 2016:947–1012.
56.
Fuentes A, Ackermann RR, Athreya S, Bolnick D, Lasisi T, Lee SH, et al. AAPA statement on race and racism. Am J Phys Anthropol. 2019;169(3):400–2.PubMedCrossRef
57.
Sankar P, Cho MK. Toward a new vocabulary of human genetic variation. Am Assoc Adv Sci. 2002;1337–8.
58.
Barbujani G. Human races: classifying people vs understanding diversity. Curr Genomics. 2005;6(4):215–26.CrossRef
59.
Collins FS. What we do and don’t know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era. Nat Genet. 2004;36(11):S13–5.PubMedCrossRef
60.
Yudell M, Roberts D, DeSalle R, Tishkoff S. Taking race out of human genetics. Science. 2016;351(6273):564–5.PubMedCrossRef
61.
62.
Duster T. A post-genomic surprise. The molecular reinscription of race in science, law and medicine. Br J Sociol. 2015;66(1):1–27.
63.
Leatherman T, Goodman A. Building on the biocultural syntheses: 20 years and still expanding. American journal of human biology : the official journal of the Human Biology Council. 2020;32(4):e23360.PubMedCrossRef
64.
Lee SS-J, Mountain J, Koenig B, Altman R, Brown M, Camarillo A, et al. The ethics of characterizing difference: guiding principles on using racial categories in human genetics. Genome Biol. 2008;9(7):404.
65.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–621.PubMedCrossRef
66.
Kauh TJ, Read JNG, Scheitler AJ. The critical role of racial/ethnic data disaggregation for health equity. Popul Res Policy Rev. 2021;40(1):1–7.
67.
Association AM. Top physician orgs urge COVID-19 mortality data by race, ethnicity. 2020.
68.
Kaufman JS. Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example. Soc Sci Med (1982). 2008;66(8):1659–69.
69.
• Wright JL, Freed GL, Hendricks-Muñoz KD, Jarvis JN, MaldonadoYA, Raphael JL, et al. Achieving equity through science and integrity: dismantling race-based medicine. Pediatr Res. 2022;91(7):1641–1644. This editorial examines the historical roots of race-based medicine and presents a case for moving away from biologized notions of race in favor of approaches that incorporate macro- and individual-level SDOH.
70.
Boulware LE, Mohottige D, Maciejewski ML. Race-free estimation of kidney function: clearing the path toward kidney health equity. JAMA. 2022;327(23):2289–91.PubMedCrossRef
71.
Essien UR, Corbie G. Getting under the skin: race-based guidelines and the pursuit of pharmacoequity. J Gen Intern Med. 2022;37(16):4035–6.PubMedCrossRef
72.
Yearby R. Race based medicine, colorblind disease: how racism in medicine harms us all. Am J Bioeth. 2021;21(2):19–27.PubMedCrossRef
73.
Rondini AC, Kowalsky RH. “First do no harm”: clinical practice guidelines, mesolevel structural racism, and medicine’s epistemological reckoning. Soc Sci Med. 2021;279:113968.PubMedCrossRef
74.
Gill JS, Kelly B, Tonelli M. Time to abolish metrics that sustain systemic racism in kidney allocation. JAMA. 2023;329(11):879–80.PubMedCrossRef
75.
• Yancy CW, Khan SS. Replacing race with social determinants of health in risk prediction—getting it right. JAMA Cardiology. 2022;7(8):856. This editorial highlights the fallacies inherent in the biologization of race and endorses an approach to risk estimation incorporating SDOH information for which race is a likely proxy in the medical literature. The authors highlight one such tool, developed by Segar et al., in which incorporation of individual-, neighborhood-, and hospital-level SDOH data using a machine learning approach improved risk prediction following HF hospitalization.
76.
Figueroa JF, Frakt AB, Jha AK. Addressing social determinants of health: time for a polysocial risk score. JAMA. 2020;323(16):1553–4.PubMedCrossRef
77.
Subramanian SV, Jones K, Kaddour A, Krieger N. Revisiting Robinson: the perils of individualistic and ecologic fallacy. Int J Epidemiol. 2009;38(2):342–60.PubMedPubMedCentralCrossRef
78.
• Segar MW, Hall JL, Jhund PS, Powell-Wiley TM, Morris AA, Kao D, et al. Machine learning-based models incorporating social determinants of health vs traditional models for predicting in-hospital mortality in patients with heart failure. JAMA Cardiol. 2022;7(8):844–854. This study presents a novel approach to estimating in-hospital heart failure mortality using a race-agnostic tool in concert with the American Heart Association Get with the Guidelines-Heart Failure registry. The authors demonstrate improved risk prediction using a machine learning algorithm with incorporation of patient- and neighborhood-level SDOH data.
Metadaten
Titel
Race as a Component of Cardiovascular Disease Risk Prediction Algorithms
verfasst von
Ramachandran S. Vasan
Shreya Rao
Edwin van den Heuvel
Publikationsdatum
15.08.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01938-y

Weitere Artikel der Ausgabe 10/2023

Current Cardiology Reports 10/2023 Zur Ausgabe

Psychological Aspects of Cardiovascular Diseases (IM Kronish, Section Editor)

Screening for Emotional Distress in Patients with Cardiovascular Disease

Structural Heart Disease (S Vakamudi, Section Editor)

Noninvasive Multimodality Imaging for the Assessment of Anomalous Coronary Artery

Pericardial Disease (AL Klein and CL Jellis, Section Editors)

Pericarditis Management in Individuals Contemplating Pregnancy, Currently Pregnant, or Breastfeeding

Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

Structural Heart Disease (S Vakamudi, Section Editor)

The Emerging Role of Intracardiac Echocardiography (ICE) in Left Atrial Appendage Closure (LAAC)

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

COVID Vaccination as a Strategy for Cardiovascular Disease Prevention

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen